Rubber band ligation (RBL) of symptomatic internal haemorrhoids, a technique refined by Barron' in the early 1960's, is a well-tolerated and effective procedure which can be performed in an outpatient setting. It is recommended as the initial mode of therapy for grades 1 to 3 haemorrhoids.2 However, the procedure is not without complications. Pain, secondary haemorrhage and life threatening pelvic sepsis are rare but have been described.3 Secondary haemorrhage occurs up to two weeks postprocedure when the bands slough off the haemorrhoidal mucosa, possibly in the presence of concurrent infection, 3 aggregation. The thienopyridine derivatives (clopidogrel and ticlodipine) also inhibit platelet aggregation but by a different mechanism. They are prodrugs, metabolised in the liver to active metabolites which are non-competitive antagonists of the platelet adenosine diphosphate receptor. Bleeding is prolonged approximately twofold. Antiplatelet effect occurs 24-48 hours after administration, with maximal inhibition obtained at 3-5 days.8 Recovery of platelet function after discontinuing these drugs is slow, 7 to 14 days or the lifespan of a circulating platelet. The combination of aspirin and clopidogrel has synergistic antiplatelet effects 8 and bleeding time is significantly increased in patients taking combined therapy.9 Surgeons and anaesthetists should exercise great caution with patients taking both antiplatelet agents.
There has been widespread adoption of the new antiplatelet agents in the management of patients with cardiovascular, cerebrovascular and peripheral vascular disease. Compared to aspirin, the CAPRIE trial demonstrated that clopidogrel had a better side effect profile and is better tolerated by patients.10 Sibon and Orgogozo recently highlighted the risk of further ischaemic strokes when anti-platelet drugs are discontinue.1I1 In their study 4.49% of all strokes were related to discontinued anti-platelet agents, with ischaemic events occurring between 6 and 10 days after discontinuation. The risk /benefit ratio for patients taking clopridogrel and undergoing surgical procedures or investigations likely to require biopsy (such as colonoscopy) need to be addressed by clinicians. In a recently published long-term follow up of patients undergoing RBL, Gordon'2 addresses the issue of increased bleeding rates post-RBL in patients taking anti-platelet agents, non-steroidal anti-inflammatory drugs or anticoagulants. Whereas adverse events may not occur in the hands of others, it is his practice to request that patients discontinue this medication for at least 1 week prior to, and 2 weeks post-RBL. 13 light of our experience we recommend a change in practice. We recommend patients discontinue clopidogrel 7 days prior to haemorrhoidal banding. For this to be practical, all colorectal referral letters should ideally be screened for patient symptoms and medication. If there is a high index of suspicion of haemorrhoidal bleeding, patients should be contacted and asked to discontinue clopridogrel 1 week prior to outpatient attendance. Patients should recommence clopidogrel 14 days post-RBL. Should, in the opinion of the clinician, the risk of discontinuing the anti-platelet agent potentially outweigh the benefit then the patient must be made fully aware of the risk of secondary haemorrhage before RBL is undertaken.
